NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SCYX

Scynexis Inc

Jul 01 • 04:00PM ET

0.7010

Dollar change +0.0262
Percentage change 3.88	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Peers: GSK PFE MRK BMY JNJ LLY GILD REGN VRTX ABBV

| Held by: VTI VXF BSVO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.58	Insider Own	4.76%	Shs Outstand	39.02M	Perf Week	-5.41%
Market Cap	27.35M	Forward P/E	1.22	EPS next Y	0.58	Insider Trans	0.00%	Shs Float	37.16M	Perf Month	-19.89%
Enterprise Value	-11.20M	PEG	-	EPS next Q	-0.19	Inst Own	30.65%	Short Float	1.68%	Perf Quarter	-26.37%
Income	-27.09M	P/S	10.40	EPS this Y	20.45%	Inst Trans	-2.54%	Short Ratio	4.48	Perf Half Y	-31.27%
Sales	2.63M	P/B	0.54	EPS next Y	264.76%	ROA	-29.10%	Short Interest	0.62M	Perf YTD	-42.07%
Book/sh	1.30	P/C	0.67	EPS next 5Y	-	ROE	-43.47%	52W High	2.29 -69.39%	Perf Year	-65.47%
Cash/sh	1.05	P/FCF	-	EPS past 3/5Y	29.37% 46.02%	ROIC	-51.51%	52W Low	0.66 6.21%	Perf 3Y	-65.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-34.22% 98.68%	Gross Margin	-	Volatility	7.10% 6.95%	Perf 5Y	-91.01%
Dividend TTM	-	EV/Sales	-4.26	EPS Y/Y TTM	-129.06%	Oper. Margin	-1377.19%	ATR (14)	0.06	Perf 10Y	-99.24%
Dividend Ex-Date	-	Quick Ratio	5.83	Sales Y/Y TTM	-98.13%	Profit Margin	-1030.04%	RSI (14)	36.78	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.83	EPS Q/Q	-1382.35%	SMA20	-11.93%	Beta	1.57	Target Price	4.67
Payout	-	Debt/Eq	0.05	Sales Q/Q	-81.28%	SMA50	-19.41%	Rel Volume	0.80	Prev Close	0.67
Employees	28	LT Debt/Eq	0.04	Earnings	May 15 AMC	SMA200	-37.09%	Avg Volume	139.00K	Price	0.70
IPO	May 02, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	43.09% 87.59%	Trades		Volume	110,615	Change	3.88%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-22-21	Initiated	Guggenheim	Buy	$25
Jan-06-21	Initiated	Cantor Fitzgerald	Overweight	$30
Jul-11-18	Upgrade	Needham	Hold → Buy	$5
Jun-27-18	Initiated	Maxim Group	Buy	$6
Oct-24-17	Initiated	Guggenheim	Buy	$6
Jul-10-17	Initiated	ROTH Capital	Buy	$8.50
May-09-17	Downgrade	Needham	Buy → Hold
Mar-03-17	Reiterated	RBC Capital Mkts	Outperform	$15 → $11
Oct-20-16	Initiated	H.C. Wainwright	Buy	$14
Oct-07-16	Upgrade	WBB Securities	Buy → Strong Buy	$8
Oct-03-16	Resumed	Brean Capital	Buy
Aug-17-16	Initiated	Guggenheim	Buy	$15
Aug-09-16	Upgrade	WBB Securities	Speculative Buy → Buy	$8
Aug-09-16	Reiterated	Needham	Buy	$16 → $10
Mar-28-16	Initiated	Brean Capital	Buy	$16
Dec-29-15	Initiated	WBB Securities	Strong Buy	$8
Dec-29-15	Initiated	WBB Securities	Speculative Buy	$8
Nov-16-15	Reiterated	RBC Capital Mkts	Outperform	$18 → $17
Jun-10-15	Initiated	Needham	Buy	$16
May-29-14	Initiated	RBC Capital Mkts	Outperform	$17

Show Previous Ratings

May-29-25 12:31AM	SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold (Insider Monkey)
May-28-25 12:23PM	Scynexis resumes dosing in Phase III MARIO study after lengthy delay (Clinical Trials Arena) +28.04%
08:30AM	SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study (GlobeNewswire)
May-15-25 04:56PM	Scynexis: Q1 Earnings Snapshot (Associated Press Finance) -19.29%
04:20PM	SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Loading…
Apr-08-25 08:00AM	SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (GlobeNewswire)
Mar-12-25 05:08PM	SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.90%
Dec-18-24 08:00AM	SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections (GlobeNewswire) -9.01%
Nov-06-24 05:55PM	Scynexis: Q3 Earnings Snapshot (Associated Press Finance)
04:30PM	SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-10-24 08:00AM	SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-07-24 05:02PM	Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc (GuruFocus.com)
Oct-03-24 08:00AM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 (GlobeNewswire)
Aug-27-24 08:00AM	SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.73%
Aug-08-24 05:44PM	Scynexis: Q2 Earnings Snapshot (Associated Press Finance) -7.85%
04:30PM	Loading…
04:30PM	SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-23-24 07:00AM	SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports (GlobeNewswire)
Jul-22-24 06:24AM	3 Stocks Under $10 With the Potential for Massive Gains (InvestorPlace)
Jul-11-24 07:00AM	3 Dirt-Cheap Drug Developers With Blockbuster Potential (InvestorPlace) +12.69%
Jul-01-24 02:18PM	7 Undervalued Biotech Stocks to Buy for Big-Time Returns (InvestorPlace)
May-31-24 11:50AM	Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025 (InvestorPlace)
May-23-24 06:42AM	3 Stocks Under $10 With Mammoth Growth Prospects (InvestorPlace) -11.46%
May-08-24 11:54PM	SCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:51PM	Scynexis: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-30-24 04:05PM	SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) (GlobeNewswire) -7.14%
Apr-16-24 11:52AM	14 Cheap Penny Stocks to Buy According to Analysts (Insider Monkey)
Apr-09-24 04:05PM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (GlobeNewswire)
Mar-28-24 11:53PM	SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:01PM	SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
04:05PM	Loading…
Jan-30-24 04:05PM	SCYNEXIS to Participate in Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire) +5.37%
Jan-29-24 05:15PM	SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference (GlobeNewswire)
Jan-05-24 08:30AM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 27, in Milan, Italy (GlobeNewswire)
Dec-27-23 09:30AM	SCYNEXIS SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Nov-27-23 10:33AM	11 Cheapest Stocks With Biggest Upside (Insider Monkey)
Nov-15-23 01:15PM	SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc. (Business Wire)
Nov-13-23 05:55PM	Scynexis: Q3 Earnings Snapshot (Associated Press Finance)
05:17PM	SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-24-23 08:00AM	SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) (GlobeNewswire)
Oct-18-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Orthofix, and Scynexis and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-16-23 08:00AM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece (GlobeNewswire) +6.12%
Oct-02-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Orthofix, and Scynexis and Encourages Investors to Contact the Firm (GlobeNewswire)
Sep-27-23 08:31PM	SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance (GlobeNewswire) +9.33% +9.00%
07:49AM	Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock? (Zacks)
Sep-25-23 08:55AM	UPDATE 4-Scynexis to recall GSK-partnered antifungal on cross contamination risk (Reuters) -34.14%
Sep-20-23 04:00AM	PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains? (Zacks) +5.01%
Sep-04-23 01:31PM	SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why (Zacks)
Aug-28-23 10:17PM	Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now (InvestorPlace) +11.96%
08:00AM	SCYNEXIS to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-23 04:59PM	Scynexis: Q2 Earnings Snapshot (AP Finance) -6.35%
04:30PM	SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-23 09:09AM	10 Best Fast Growing Penny Stocks to Buy Now (Insider Monkey)
Jul-20-23 09:58AM	SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China (GlobeNewswire) +5.69%
Jun-26-23 02:20PM	Deadly Fungi Are Becoming More Common and Were Running Out of Ways to Treat Them (The Wall Street Journal)
07:00AM	Doctors Desperately Need Drugs to Kill Deadly Fungi. Its an Uphill Fight. (The Wall Street Journal)
Jun-21-23 07:00AM	SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK (GlobeNewswire)
Jun-15-23 04:10PM	SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
May-19-23 09:22AM	WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens (Newsfile)
May-12-23 08:00AM	SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets) (GlobeNewswire)
May-11-23 08:45AM	Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:37AM	Scynexis: Q1 Earnings Snapshot (AP Finance)
07:00AM	SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-23 03:38PM	SCYNEXIS, Inc.'s (NASDAQ:SCYX) largest shareholders are individual investors with 51% ownership, institutions own 48% (Simply Wall St.)
Apr-13-23 08:30AM	SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark (GlobeNewswire)
Apr-11-23 01:33PM	We Might See A Profit From SCYNEXIS, Inc. (NASDAQ:SCYX) Soon (Simply Wall St.)
Mar-31-23 12:31PM	Scynexis (SCYX) Inks Antifungal Drug Deal With GSK (Zacks)
08:30AM	SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-30-23 01:12PM	GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks (Benzinga) +76.05%
09:36AM	Anti-Fungal Maker Scynexis Stock Soars on GSK Deal (Barrons.com)
07:05AM	GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection (GlobeNewswire)
Mar-22-23 09:25AM	CDC Rings Alarm About Deadly Fungus. 6 Things to Know. (Barrons.com) +28.21%
07:06AM	SCYNEXIS, Inc. (NASDAQ:SCYX) insiders are still down US$113k after purchasing last year, recent gain helped regain some losses (Simply Wall St.)
Mar-01-23 04:03PM	Analyst Sees Multiple Chances With Over 300% Upside Potential For This Fungal Infections Stock (Benzinga) +16.11%
Jan-14-23 07:43AM	SCYNEXIS (NASDAQ:SCYX) shareholders are up 14% this past week, but still in the red over the last five years (Simply Wall St.)
Dec-01-22 08:00AM	SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis (GlobeNewswire) -10.17%
Nov-30-22 08:30AM	SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi (GlobeNewswire)
Nov-17-22 08:30AM	SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats (GlobeNewswire)
Nov-11-22 05:37AM	SCYNEXIS Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-09-22 08:15AM	Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -19.64%
07:00AM	SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-22 08:30AM	SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of Fungi (GlobeNewswire)
Nov-03-22 08:30AM	Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Womens Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection (GlobeNewswire)
Nov-02-22 10:01AM	Earnings Preview: Scynexis (SCYX) Q3 Earnings Expected to Decline (Zacks)
Nov-01-22 08:30AM	SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9 (GlobeNewswire)
Oct-25-22 08:30AM	Biopharma Veteran Ivor Macleod Joins SCYNEXIS as Chief Financial Officer (GlobeNewswire) +5.41%
Oct-24-22 08:30AM	SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022 (GlobeNewswire) -7.11%
Oct-20-22 07:00AM	SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal (GlobeNewswire) -14.97%
Oct-11-22 08:30AM	SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022 (GlobeNewswire)
Oct-07-22 09:25AM	Great news for SCYNEXIS, Inc. (NASDAQ:SCYX): Insiders acquired stock in large numbers last year (Simply Wall St.)
Sep-09-22 08:30AM	SCYNEXIS to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Sep-08-22 08:30AM	SCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting (GlobeNewswire)
Sep-01-22 08:30AM	SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022 (GlobeNewswire)
Aug-15-22 08:15AM	Scynexis (SCYX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-09-22 08:30AM	SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15 (GlobeNewswire) -6.90%
Aug-04-22 08:30AM	SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting (GlobeNewswire) +8.70%
Aug-01-22 08:30AM	SCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME® (ibrexafungerp tablets) for Prevention of Recurrent Vaginal Yeast Infections (GlobeNewswire)
Jul-19-22 08:30AM	SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the ISSVD XXVI World Congress and International Vulvovaginal Disease Update (GlobeNewswire)
Jul-14-22 08:30AM	SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update (GlobeNewswire)
Jun-29-22 07:06AM	The past five years for SCYNEXIS (NASDAQ:SCYX) investors has not been profitable (Simply Wall St.)

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Federated Hermes Kaufmann Fund	10% Owner	Dec 18 '24	Proposed Sale	1.23	4,709	5,792		Dec 18 02:14 PM
Federated Hermes Kaufmann Smal	10% Owner	Dec 18 '24	Proposed Sale	1.23	128,957	158,617		Dec 18 02:13 PM
Federated Hermes Kaufmann Fund	10% Owner	Dec 18 '24	Proposed Sale	1.23	166,334	204,591		Dec 18 02:11 PM
Federated Hermes Kaufmann Fund	10% Owner	Dec 11 '24	Proposed Sale	1.23	10,988	13,515		Dec 11 03:57 PM
Federated Hermes Kaufmann Smal	10% Owner	Dec 11 '24	Proposed Sale	1.23	300,899	370,106		Dec 11 03:41 PM
Federated Hermes Kaufmann Fund	10% Owner	Dec 11 '24	Proposed Sale	1.23	388,113	477,379		Dec 11 03:40 PM
Angulo Gonzalez David	Chief Executive Officer	Sep 12 '24	Buy	1.37	20,000	27,400	507,871	Sep 16 08:00 AM
Federated Hermes Kaufmann Fund	10% Owner	Aug 22 '24	Proposed Sale	1.77	9,700	17,169		Aug 27 05:30 PM
Federated Hermes Kaufmann Smal	10% Owner	Aug 22 '24	Proposed Sale	1.77	272,000	481,440		Aug 27 05:29 PM
Federated Hermes Kaufmann Fund	10% Owner	Aug 22 '24	Proposed Sale	1.77	338,000	598,260		Aug 27 05:28 PM
Federated Hermes Kaufmann Fund	10% Owner	Aug 22 '24	Proposed Sale	1.77	9,700	17,169		Aug 22 04:49 PM
Federated Hermes Kaufmann Smal	10% Owner	Aug 22 '24	Proposed Sale	1.77	272,000	481,440		Aug 22 04:48 PM
Federated Hermes Kaufmann Fund	10% Owner	Aug 22 '24	Proposed Sale	1.77	338,000	598,260		Aug 22 04:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCYX

Scynexis Inc

Upgrade your FINVIZ experience